Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers.
Juanita Lopez(Institute of Cancer Research), Joachim P. Steinbach(Goethe University Frankfurt), T.R. Jeffry Evans(University of Glasgow), Benjamin Wunderlich, Heinz Läubli(University of Basel), Kirk D. Beebe, Peter Hau(University Hospital Regensburg), Thomas Kaindl(Basilea Pharmaceutica (Switzerland)), Antje Wick(Heidelberg University), Patrick Roth(University Hospital of Zurich), Marc Engelhardt(Basilea Pharmaceutica (Switzerland)), Ruth Plummer(National Health Service), Wing Yau(Royal Marsden NHS Foundation Trust), Joel R. Eisner(G1 Therapeutics (United States)), Heidi A. Lane(Basilea Pharmaceutica (Switzerland)), Thomas Hundsberger(University of St.Gallen), Ghazaleh Tabatabai(Goethe University Frankfurt), Simon Haefliger(University of Bern), Lucy Brazil(St Thomas' Hospital), Paul M. Clément(Universitair Ziekenhuis Leuven)
Cited by 1
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994